Contracts › 75N95022F00003
75N95022F00003: Office-Based Methadone Vs Buprenorphine to Address Retention in Medication for Opioid Use Disorder (MOUD)-A Pragmatic Hybrid Effectiveness/Implementation Trial (CTN-013). 09/28/2022 - 08/04/2025. DSC6. 75N95022F00003 (TO3).
Awarded to The Emmes Company, Llc by National Institutes of Health (NIH).
$1.9Mobligated
$1.9Mpotential value
31 January 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N95022F00003 |
|---|---|
| Vehicle | 75N95022D00017 |
| Awardee | The Emmes Company, Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Period of performance | 28 September 2022 to 31 January 2027 |
| Potential end | 31 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record